<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Journal of microbiology, epidemiology and immunobiology</journal-id><journal-title-group><journal-title xml:lang="en">Journal of microbiology, epidemiology and immunobiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Журнал микробиологии, эпидемиологии и иммунобиологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">0372-9311</issn><issn publication-format="electronic">2686-7613</issn><publisher><publisher-name xml:lang="en">Central Research Institute for Epidemiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">18823</article-id><article-id pub-id-type="doi">10.36233/0372-9311-614</article-id><article-id pub-id-type="edn">NRAEKS</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL RESEARCHES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Molecular and biological characterization of <italic>Streptococcus pneumoniae</italic> isolates from patients with pneumococcal meningitis</article-title><trans-title-group xml:lang="ru"><trans-title>Молекулярно-биологическая характеристика изолятов <italic>Streptococcus pneumoniae</italic>, выделенных от больных пневмококковым менингитом</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9195-8764</contrib-id><name-alternatives><name xml:lang="en"><surname>Chagaryan</surname><given-names>Aida N.</given-names></name><name xml:lang="ru"><surname>Чагарян</surname><given-names>Аида Нуримановна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Biol.), researcher, Laboratory of antibiotic resistance, Research Institute of Antimicrobial Chemotherapy</p></bio><bio xml:lang="ru"><p>кандидат биол. наук, научный сотрудник лаб. антибиотикорезистентности НИИ антимикробной химиотерапии</p></bio><email>aida.chagaryan@antibiotic.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9392-0732</contrib-id><name-alternatives><name xml:lang="en"><surname>Ivanchik</surname><given-names>Natali V.</given-names></name><name xml:lang="ru"><surname>Иванчик</surname><given-names>Натали Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), researcher, Laboratory of antibiotic resistance, Research Institute of Antimicrobial Chemotherapy</p></bio><bio xml:lang="ru"><p>кандидат мед. наук, старший научный сотрудник лаб. антибиотикорезистентности НИИ антимикробной химиотерапии</p></bio><email>natali.ivanchik@antibiotic.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9562-2096</contrib-id><name-alternatives><name xml:lang="en"><surname>Kuzmenkov</surname><given-names>Alexey Yu.</given-names></name><name xml:lang="ru"><surname>Кузьменков</surname><given-names>Алексей Юрьевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Sci. (Med.), Professor, Deputy director, Associate Professor, Microbiology department, Institute of Antimicrobial Chemotherapy</p></bio><bio xml:lang="ru"><p>доктор мед. наук, профессор каф. микробиологии, зам. директора по стратегическим разработкам НИИ антимикробной химиотерапии</p></bio><email>alexey.kuzmenkov@antibiotic.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8728-1113</contrib-id><name-alternatives><name xml:lang="en"><surname>Kozlov</surname><given-names>Roman S.</given-names></name><name xml:lang="ru"><surname>Козлов</surname><given-names>Роман Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D<italic>.</italic> (Med.), Professor, Director, Research Institute of Antimicrobial Chemotherapy, Chancellor</p></bio><bio xml:lang="ru"><p>доктор мед. наук, профессор, ректор, директор НИИ антимикробной химиотерапии</p></bio><email>roman.kozlov@antibiotic.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4481-2249</contrib-id><name-alternatives><name xml:lang="en"><surname>Gaponova</surname><given-names>Irina I.</given-names></name><name xml:lang="ru"><surname>Гапонова</surname><given-names>Ирина Игоревна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>research laboratory assistant, Scientific group for the development of new methods for detecting genetic polymorphisms</p></bio><bio xml:lang="ru"><p>лаборант-исследователь научной группы разработки новых методов выявления генетических полиморфизмов</p></bio><email>gaponova@cmd.su</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8207-9215</contrib-id><name-alternatives><name xml:lang="en"><surname>Mironov</surname><given-names>Konstantin O.</given-names></name><name xml:lang="ru"><surname>Миронов</surname><given-names>Константин Олегович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Sci. (Med.), Head, Group for the development of new methods for detecting genetic polymorphisms</p></bio><bio xml:lang="ru"><p>доктор мед. наук, рук. научной группы разработки новых методов выявления генетических полиморфизмов</p></bio><email>mironov@pcr.ru</email><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute of Antimicrobial Chemotherapy, Smolensk State Medical University</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт антимикробной химиотерапии Смоленского государственного медицинского университета</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Central Research Institute of Epidemiology</institution></aff><aff><institution xml:lang="ru">Центральный научно-исследовательский институт эпидемиологии Роспотребнадзора</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-05-12" publication-format="electronic"><day>12</day><month>05</month><year>2025</year></pub-date><volume>102</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>150</fpage><lpage>161</lpage><history><date date-type="received" iso-8601-date="2025-05-10"><day>10</day><month>05</month><year>2025</year></date><date date-type="accepted" iso-8601-date="2025-05-10"><day>10</day><month>05</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Chagaryan A.N., Ivanchik N.V., Kuzmenkov A.Y., Kozlov R.S., Gaponova I.I., Mironov K.O.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Чагарян А.Н., Иванчик Н.В., Кузьменков А.Ю., Козлов Р.С., Гапонова И.И., Миронов К.О.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Chagaryan A.N., Ivanchik N.V., Kuzmenkov A.Y., Kozlov R.S., Gaponova I.I., Mironov K.O.</copyright-holder><copyright-holder xml:lang="ru">Чагарян А.Н., Иванчик Н.В., Кузьменков А.Ю., Козлов Р.С., Гапонова И.И., Миронов К.О.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://microbiol.crie.ru/jour/article/view/18823">https://microbiol.crie.ru/jour/article/view/18823</self-uri><abstract xml:lang="en"><p><bold>The</bold><bold> </bold><bold>aim</bold><bold> </bold>of the study is to provide key characteristics of <italic>Streptococcus</italic><italic> </italic><italic>pneumoniae</italic> isolates circulating in Russia in 2015–2020 and isolated from pneumococcal meningitis patients based on high-throughput sequencing data, including global pneumococcal sequence clusters, serotypes, virulence factors and genetic determinants of resistance, in comparison with clinical data on antimicrobial susceptibility.</p> <p><bold>Materials</bold><bold> </bold><bold>and</bold><bold> </bold><bold>methods</bold><bold>.</bold> We studied 68 invasive <italic>S</italic><italic>. </italic><italic>pneumoniae</italic><italic> </italic>isolates from blood and cerebrospinal fluid of patients with bacterial meningitis in different regions of Russia in 2015–2020. Species identification was performed taking into account the morphology of colonies on blood agar, the presence of α-hemolysis, negative catalase reaction, sensitivity to optoquine, and positive latex-agglutination results. The sensitivity of isolates to antimicrobials was determined by microdilution in broth, and sensitivity categories were determined based on borderline values of minimum inhibitory concentrations (MICs). Whole genome sequencing of <italic>S</italic><italic>. </italic><italic>pneumoniae</italic> isolates, analysis of isolates for penicillin-binding protein signature, determination of global pneumococcal sequence clusters, MLST alleles, serotypes, sequence types and acquired resistance genes (<italic>mefA</italic>, <italic>ermB</italic>, <italic>tetM</italic>, <italic>folA</italic><italic>/</italic><italic>P</italic>, <italic>cat</italic>), identification of virulence genes were carried out.</p> <p><bold>Results</bold><bold>. </bold>Twenty-eight GPSCs, 45 sequence types and 27 serotypes were identified. The coverage rates of PPV-23 and PCV-13 were 78% and 59%, respectively. Serotypes 3 (18%), 19F (9%), 23F (7%) and 15B (6%) were predominant. The GPSC12 lineage (serotype 3) was predominant (43%). Lineages expressing vaccine serotypes GPSC1(19F), GPSC6(14), GPSC13(6A), GPSC904(14) and GPSC10(19F) exhibited multiple antimicrobial resistance, including penicillin resistance. The resistant lineages expressing non-vaccine serotypes were GPSC230 (13) and GPSC177 (35F). In most cases, genotypic and phenotypic resistance to penicillin (increased MICs of β-lactams correlated with types of penicillin-binding proteins), erythromycin (<italic>ermB</italic>, <italic>mefA</italic>, <italic>ermB</italic>/<italic>mefA</italic>), clindamycin (<italic>ermB</italic>) and tetracycline (<italic>tetM</italic>), and trimethoprim-sulfamethoxazole (<italic>folA</italic>, <italic>folP</italic>) was found to be consistent. The virulence genes <italic>cbpG</italic>, <italic>lytA</italic>, <italic>pce</italic>/<italic>cbpE</italic>, <italic>pavA</italic>, <italic>pfbA</italic>, <italic>ply</italic>, <italic>hysA</italic>, <italic>nanA</italic> and <italic>cps</italic><italic>4</italic><italic>A</italic> were detected in all isolates. Zinc metalloproteinase C was detected in 13% of isolates.</p> <p><bold>Conclusion</bold><bold>.</bold> A high diversity of serotypes and lineages among pneumococcal isolates from meningitis patients was revealed. Out of the 68 <italic>S</italic><italic>. </italic><italic>pneumoniae</italic> isolates from patients with bacterial meningitis, more than 17% belonged to non-vaccine serotypes. The results of phenotypic and genotypic antimicrobial resistance comparison were characterized by good concordance, which indicates the necessity for further study of the possibility of using whole-genome sequencing as a diagnostic tool to identify resistance mechanisms in clinical isolates of pneumococci.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель </bold>работы — дать ключевые характеристики изолятов <italic>Streptococcus</italic><italic> </italic><italic>pneumoniae</italic><italic>,</italic> циркулирующих на территории России в 2015–2020 гг. и выделенных от больных пневмококковым менингитом, на основании данных высокопроизводительного секвенирования, включая глобальные кластеры пневмококковых последовательностей, серотипы, факторы вирулентности и генетические детерминанты резистентности, в сравнении с клиническими данными по чувствительности к антимикробным препаратам (АМП).</p> <p><bold>Материалы и методы.</bold> Исследовано 68 инвазивных изолятов <italic>S</italic><italic>. </italic><italic>pneumoniae</italic><italic>,</italic> выделенных из крови и ликвора пациентов с бактериальным менингитом в разных регионах России в 2015–2020 гг. Видовую идентификацию проводили с учётом морфологии колоний на кровяном агаре, наличия α-гемолиза, отрицательной каталазной реакции, чувствительности к оптохину, положительных результатов латекс-агглютинации. Чувствительность изолятов к АМП определяли методом микроразведений в бульоне, категории чувствительности — на основании пограничных значений минимальных подавляющих концентраций (МПК). Проводили полногеномное секвенирование изолятов <italic>S</italic><italic>. </italic><italic>pneumoniae</italic>, анализ изолятов на сигнатуру пенициллинсвязывающих белков, определение глобальных кластеров пневмококковых последовательностей, аллелей MLST, серотипов, сиквенс-типов и генов приобретённой резистентности (<italic>mefA</italic><italic>, </italic><italic>ermB</italic><italic>,</italic> <italic>tetM</italic>, <italic>folA</italic><italic>/</italic><italic>P</italic><italic>, </italic><italic>cat</italic>), идентифицировали гены вирулентности.</p> <p><bold>Результаты. </bold>Выявлены 28 GPSC, 45 сиквенс-типов и 27 серотипов. Степень охвата ППВ-23 и ПКВ-13 составила 78 и 59% соответственно. Доминировали серотипы 3 (18%), 19F (9%), 23F (7%) и 15В (6%). Преобладала (43%) линия GPSC12 (серотип 3). Линии, экспрессирующие вакцинные серотипы GPSC1(19F), GPSC6(14), GPSC13(6A), GPSC904(14) и GPSC10(19F), обладали множественной антимикробной резистентностью, включая резистентность к пенициллину. Резистентные линии, экспрессирующие невакцинные серотипы, — GPSC230 (13) и GPSC177 (35F). В большинстве случаев установлено соответствие генотипической и фенотипической резистентности к пенициллину (повышенные МПК β-лактамов коррелировали с типами пенициллинсвязывающих белков), эритромицину (<italic>ermB</italic><italic>, </italic><italic>mefA</italic><italic>, </italic><italic>ermB</italic><italic>/</italic><italic>mefA</italic>), клиндамицину (<italic>ermB</italic>) и тетрациклину (<italic>tetM</italic>) и триметоприму-сульфаметоксазолу (<italic>folA</italic><italic>, </italic><italic>folP</italic><italic>)</italic>. У всех изолятов обнаружены гены вирулентности <italic>cbpG</italic><italic>, </italic><italic>lytA</italic><italic>, </italic><italic>pce</italic><italic>/</italic><italic>cbpE</italic><italic>, </italic><italic>pavA</italic><italic>, </italic><italic>pfbA</italic><italic>, </italic><italic>ply</italic><italic>, </italic><italic>hysA</italic><italic>, </italic><italic>nanA</italic><italic> </italic>и<italic> </italic><italic>cps</italic><italic>4</italic><italic>A</italic>. Цинковая металлопротеиназа С обнаружена у 13% изолятов.</p> <p><bold>Заключение.</bold> Выявлено высокое разнообразие серотипов и линий среди изолятов пневмококков, выделенных у больных менингитом. Из 68 изолятов <italic>S</italic><italic>. </italic><italic>pneumoniae</italic>, выделенных у пациентов с бактериальным менингитом, более 17% относились к невакцинным серотипам. Результаты сопоставления фенотипической и генотипической антимикробной резистентности характеризовались хорошей конкордантностью, что указывает на необходимость дальнейшего изучения возможности использования полногеномного секвенирования в качестве диагностического инструмента для выявления механизмов резистентности у клинических изолятов пневмококков.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Streptococcus pneumoniae</kwd><kwd>invasive pneumococcal infections</kwd><kwd>whole-genome sequencing</kwd><kwd>multilocus sequencing-typing</kwd><kwd>antimicrobial resistance</kwd><kwd>penicillin-binding proteins</kwd><kwd>global pneumococcal sequence cluster</kwd><kwd>serotypes</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>Streptococcus pneumoniae</kwd><kwd>инвазивные пневмококковые инфекции</kwd><kwd>полногеномное секвенирование</kwd><kwd>мультилокусное секвенирование-типирование</kwd><kwd>резистентность к антимикробным препаратам</kwd><kwd>пенициллинсвязывающие белки</kwd><kwd>глобальный кластер пневмококковых последовательностей</kwd><kwd>серотипы</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Principi N., Di Cara G., Bizzarri I., et al. Prevention of invasive pneumococcal disease: problems emerged after some years of the 13-valent pneumococcal conjugate vaccine use. Curr. Infect. Dis. Rep. 2018;20(1):1. DOI: https://doi.org/10.1007/s11908-018-0607-z</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Briles D.E., Paton J.C., Mukerji R., et al. Pneumococcal vaccines. Microbiol. Spectr. 2019;7(6):10.1128/microbiolspec.gpp3-0028-2018. DOI: https://doi.org/10.1128/microbiolspec.GPP3-0028-2018</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Chen H., Matsumoto H., Horita N., et al. Prognostic factors for mortality in invasive pneumococcal disease in adults: a systematic review and meta-analysis. Sci. Rep. 2021;11(1):11865. DOI: https://doi.org/10.1038/s41598-021-91234-y</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Ganaie F., Saad JS., McGee L., et al. A new pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral streptococcus. mBio. 2020;11(3):e00937-20. DOI: https://doi.org/10.1128/mbio.00937-20</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Salvadori G., Junges R., Morrison D.A., Petersen F.C. Competence in Streptococcus pneumoniae and close commensal relatives: mechanisms and implications. Front. Cell. Infect. Microbiol. 2019;9:94. DOI: https://doi.org/10.3389/fcimb.2019.00094</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Протасова И.Н., Бахарева Н.В., Перьянова О.В. и др. Молекулярно-эпидемиологическая характеристика и резистентность пневмококков у детей дошкольного возраста. Сибирское медицинское обозрение. 2018;(3):73–9. Protasova I.N., Bakhareva N.V., Peryanova O.V., et al. Molecular-epidemiological characteristics and resistance of pneumococcus in children of preschool age. Siberian Medical Review. 2018;(3):73–9. DOI: https://doi.org/10.20333/2500136-2018-3-73-79 EDN: https://elibrary.ru/xserud</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Sidorenko S., Rennert W., Lobzin Y., et al. Multicenter study of serotype distribution of Streptococcus pneumoniae nasopharyngeal isolates from healthy children in the Russian Federation after introduction of PCV13 into the National Vaccination Calendar. Diagn. Microbiol. Infect. Dis. 2020;96(1):114914. DOI: https://doi.org/10.1016/j.diagmicrobio.2019.114914</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Протасова И.Н., Мартынова Г.П., Ильенкова Н.А. и др. Этиологическая роль и молекулярно-генетические особенности Streptococcus pneumoniae при инфекционных заболеваниях у детей. Детские инфекции. 2020;19(1):7–12. DOI: https://doi.org/10.22627/2072-8107-2020-19-1-7-12 EDN: https://elibrary.ru/dwibms</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Миронов К.О., Гапонова И.И., Корчагин В.И. и др. Антигенная и генетическая характеристика штаммов Streptococcus pneumoniae, выделенных от больных инвазивными и неинвазивными пневмококковыми инфекциями, с использованием высокопроизводительного секвенирования. Журнал микробиологии, эпидемиологии и иммунобиологии. 2021;98(5):512–8. Mironov K.O., Gaponova I.I., Korchagin V.I., et al. Antigenic and genetic characterization of Streptococcus pneumoniae strains isolated from patients with invasive and non-invasive pneumococcal infections by using high-throughput sequencing. Journal of Microbiology, Epidemiology and Immunobiology. 2021;98(5):512–8. DOI: https://doi.org/10.36233/0372-9311-144, EDN: https://elibrary.ru/kvjhkq</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Vohrnová S., Kozáková J. Posibilities for use of whole genome sequencing (WGS) for the analysis of Streptococcus pneumoniae isolates. Epidemiol. Mikrobiol. Imunol. 2024;73(1):30–6. DOI: https://doi.org/10.61568/emi/11-6254/20240123/136240 (in Czech)</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Иванчик Н.В., Чагарян А.Н., Сухорукова М.В. и др. Антибиотикорезистентность клинических штаммов Streptococcus pneumoniae в России: результаты многоцентрового эпидемиологического исследования «ПеГАС 2014–2017». Клиническая микробиология и антимикробная химиотерапия. 2019;21(3):230–7. Ivanchik N.V., Chagaryan A.N., Sukhorukova M.V., et al. Antimicrobial resistance of clinical Streptococcus pneumoniae isolates in Russia: the results of multicenter epidemiological study «Pehasus 2014–2017». Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(3):230–7. DOI: https://doi.org/10.36488/cmac.2019.3.230-237, EDN: https://elibrary.ru/hlaxrl</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Миронов К.О., Корчагин В.И., Михайлова Ю.В. и др. Характеристика штаммов Streptococcus рneumoniae, выделенных от больных инвазивными пневмококковыми инфекциями, с использованием высокопроизводительного секвенирования. Журнал микробиологии, эпидемиологии и иммунобиологии. 2020;97(2):113–8. Mironov K.O., Korchagin V.I., Mikhailova Yu.V., et al. Characterization of Streptococcus pneumoniae strains causing invasive infections using whole-genome sequencing. Journal of Microbiology, Epidemiology and Immunobiology. 2020;97(2):113–8. DOI: https://doi.org/10.36233/0372-9311-2020-97-2-113-118 EDN: https://elibrary.ru/lnxmqy</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kawaguchiya M., Urushibara N., Aung M.S., et al. Genetic characterization of penicillin-binding proteins of nonencapsulated Streptococcus pneumoniae in the postpneumococcal conjugate vaccine era in Japan. Int. J. Infect. Dis. 2022;120:174–6. DOI: https://doi.org/10.1016/j.ijid.2022.04.033</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Grant L.R., Slack M.P.E., Theilacker C., et al. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies. Vaccine. 2023;41(38):5662–9. DOI: https://doi.org/10.1016/j.vaccine.2023.08.001</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Brandileone M.C.C., Almeida S.C.G., Minamisava R., Andrade A.L. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of a 10-valent pneumococcal conjugate vaccine in Brazil. Vaccine. 2018;36(19):2559–66. DOI: https://doi.org/10.1016/j.vaccine.2018.04.010</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Almeida S.C.G., Cassiolato A.P., Dias U.J., et al. Molecular characterization of invasive Streptococcus pneumoniae isolated in pre (2005–2009) and post (2011–2015) 10-valent pneumococcal conjugate vaccine introduction in Brazil. In: 37th Annual Meeting of the European Society for Paediatric Infectious Diseases. Ljubljana, Slovenia;2019.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Shenoy A.T., Beno S.M., Brissac T., et al. Severity and properties of cardiac damage caused by Streptococcus pneumoniae are strain dependent. PLoS One. 2018;13(9):e0204032. DOI: https://doi.org/10.1371/journal.pone.0204032</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Andrews N., Kent A., Amin-Chowdhury Z., et al. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006–2018. Vaccine. 2019;37(32):4491–8. DOI: https://doi.org/10.1016/j.vaccine.2019.06.071</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Wijayasri S., Hillier K., Lim GH., et al. The shifting epidemiology and serotype distribution of invasive pneumococcal disease in Ontario, Canada, 2007–2017. PLoS One. 2019;14(12):e0226353. DOI: https://doi.org/10.1371/journal.pone.0226353</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Goettler D., Streng A., Kemmling D., et al. Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany. Vaccine. 2020;38(3):570–7. DOI: https://doi.org/10.1016/j.vaccine.2019.10.056</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Babb R., Doyle C.R., Pirofski L.A. Isolation and characterization of human monoclonal antibodies to pneumococcal capsular polysaccharide 3. Microbiol. Spectr. 2021;9(3):e0144621. DOI: https://doi.org/10.1128/Spectrum.01446-21</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Lo SW., Gladstone RA., van Tonder AJ., et al. Pneumococcal lineages associated with serotype replacement and antibiotic resistance in childhood invasive pneumococcal disease in the post-PCV13 era: an international whole-genome sequencing study. Lancet Infect. Dis. 2019;19(7):759–69. DOI: https://doi.org/10.1016/s1473-3099(19)30297-x</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Kandasamy R., Voysey M., Collins S., et al. Persistent circulation of vaccine serotypes and serotype replacement after 5 years of infant immunization with 13-valent pneumococcal conjugate vaccine in the United Kingdom. J. Infect. Dis. 2020;221(8):1361–70. DOI: https://doi.org/10.1093/infdis/jiz178</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Løchen A., Croucher N.J., Anderson R.M. Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high-income settings reduce the benefit of expanding vaccine valency. Sci. Rep. 2020;10(1):18977. DOI: https://doi.org/10.1038/s41598-020-75691</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Kwun M.J., Ion A.V., Cheng H.C., et al. Post-vaccine epidemiology of serotype 3 pneumococci identifies transformation inhibition through prophage-driven alteration of a non-coding RNA. Genome Med. 2022;14(1):144. DOI: https://doi.org/10.1186/s13073-022-01147-2</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Butić I., Gužvinec M., Jelić M., et al. Serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates among Croatian adults during a fifteen-year period (2005–2019). Croat. Med. J. 2022;63(2):156–65. DOI: https://doi.org/10.3325/cmj.2022.63.156</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Azarian T., Mitchell P.K., Georgieva M., et al. Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci. PLoS Pathog. 2018;14(11):e1007438. DOI: https://doi.org/10.1371/journal.ppat.1007438</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Sheppard C.L., Groves N., Andrews N., et al. The genomics of Streptococcus рneumoniae carriage isolates from UK children and their household contacts, pre-PCV7 to post-PCV13. Genes (Basel). 2019;10(9):687. DOI: https://doi.org/10.3390/genes10090687</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Groves N., Sheppard CL., Litt D., et al. Evolution of Streptococcus pneumoniae serotype 3 in England and Wales: a major vaccine evader. Genes (Basel). 2019;10(11):845. DOI: https://doi.org/10.3390/genes10110845</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Suaya J.A., Mendes R.E., Sings R.E., et al. Streptococcus pneumoniae serotype distribution and antimicrobial nonsusceptibility trends among adults with pneumonia in the United States, 2009‒2017. J. Infect. 2020;81(4):557–66. DOI: https://doi.org/10.1016/j.jinf.2020.07.035</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Sanapala S.R., Seco B.M.S., Baek J.Y., et al. Chimeric oligosaccharide conjugate induces opsonic antibodies against Streptococcus pneumoniae serotypes 19A and 19F. Chem. Sci. 2020;11(28):7401–7. DOI: https://doi.org/10.1039/d0sc02230f</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Downs SL., Olwagen CP., Van Der Merwe L., et al. Streptococcus pneumoniae and other bacterial nasopharyngeal colonization seven years post-introduction of 13-valent pneumococcal conjugate vaccine in South African children. Int. J. Infect. Dis. 2023;134: 45–52. DOI: https://doi.org/10.1016/j.ijid.2023.05.016</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Golden A.R., Adam H.J., Baxter M., et al. Whole genome characterization of Streptococcus pneumoniae from respiratory and blood cultures collected from Canadian hospitals before and after PCV-13 implementation in Canada: Focus on serotypes 22F and 33F from CANWARD 2007–2018. Vaccine. 2021;39(39): 5474–83. DOI: https://doi.org/10.1016/j.vaccine.2021.08.061</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Yamba Yamba L., Uddén F., Fuursted K., et al. Extensive/multidrug-resistant pneumococci detected in clinical respiratory tract samples in Southern Sweden are closely related to international multidrug-resistant lineages. Front. Cell. Infect. Microbiol. 2022;12:824449. DOI: https://doi.org/10.3389/fcimb.2022.824449</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Gladstone R.A., Lo S.W., Lees J.A., et al. International genomic definition of pneumococcal lineages, to contextualise disease, antibiotic resistance and vaccine impact. EBioMedicine. 2019;43:338–46. DOI: https://doi.org/10.1016/j.ebiom.2019.04.021</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Lekhuleni C., Ndlangisa K., Gladstone R.A., et al. Impact of pneumococcal conjugate vaccines on invasive pneumococcal disease-causing lineages among South African children. Nat. Commun. 2024;15(1):8401. DOI: https://doi.org/10.1038/s41467-024-52459-3</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Nagaraj G., Govindan V., Ganaie F., et al. Streptococcus pneumoniae genomic datasets from an Indian population describing pre-vaccine evolutionary epidemiology using a whole genome sequencing approach. Microb. Genom. 2021;7(9):000645. DOI: https://doi.org/10.1099/mgen.0.000645</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Lo S.W., Gladstone R.A., van Tonder A.J., et al. A mosaic tetracycline resistance gene tet(S/M) detected in an MDR pneumococcal CC230 lineage that underwent capsular switching in South Africa. J. Antimicrob. Chemother. 2020;75(3):512–20. DOI: https://doi.org/10.1093/jac/dkz477</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Gagetti P., Lo SW., Hawkins PA., et al. Population genetic structure, serotype distribution and antibiotic resistance of Streptococcus pneumoniae causing invasive disease in children in Argentina. Microb. Genom. 2021;7(9):000636. DOI: https://doi.org/10.1099/mgen.0.000636</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Lo S.W., Mellor K., Cohen R., Alonso A.R. Emergence of a multidrug-resistant and virulent Streptococcus pneumoniae lineage mediates serotype replacement after PCV13: an international whole-genome sequencing study. Lancet Microbe. 2022;3(10):e735–43. DOI: https://doi.org/10.1016/s2666-5247(22)00158-6</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Egorova E., Kumar N., Gladstone R.A., et al. Key features of pneumococcal isolates recovered in Central and Northwestern Russia in 2011–2018 determined through whole-genome sequencing. Microb. Genom. 2022;8(9):mgen000851. DOI: https://doi.org/10.1099/mgen.0.000851</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Beheshti M., Jabalameli F., Feizabadi M.M., et al. Molecular characterization, antibiotic resistance pattern and capsular types of invasive Streptococcus pneumoniae isolated from clinical samples in Tehran, Iran. BMC Microbiol. 2020;20(1):167. DOI: https://doi.org/10.1186/s12866-020-01855-y</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Zhou M., Wang L., Wang Z., et al. Molecular characterization of penicillin-binding protein2x, 2b and 1a of Streptococcus pneumoniae causing invasive pneumococcal diseases in China: a multicenter study. Front. Microbiol. 2022;13:838790. DOI: https://doi.org/10.3389/fmicb.2022.838790</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Ouldali N., Varon E., Levy C., et al. Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study. Lancet Infect. Dis. 2021;21(1):137–47. DOI: https://doi.org/10.1016/S1473-3099(20)30165-1</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Andrejko K., Ratnasiri B., Lewnard J.A. Association of pneumococcal serotype with susceptibility to antimicrobial drugs: a systematic review and meta-analysis. Clin. Infect. Dis. 2022;75(1):131–40. DOI: https://doi.org/10.1093/cid/ciab852</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Balsells E., Dagan R., Yildirim I., et al. The relative invasive disease potential of Streptococcus pneumoniae among children after PCV introduction: a systematic review and meta-analysis. J. Infect. 2018;77(5):368–78. DOI: https://doi.org/10.1016/j.jinf.2018.06.004</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Amin-Chowdhury Z., Collins S., Sheppard C., et al. Characteristics of invasive pneumococcal disease caused by emerging serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in England: a prospective observational cohort study, 2014–2018. Clin. Infect. Dis. 2020;71(8):e235–43. DOI: https://doi.org/10.1093/cid/ciaa043</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Hansen C.B., Fuursted K., Valentiner-Branth P., et al. Molecular characterization and epidemiology of Streptococcus pneumoniae serotype 8 in Denmark. BMC Infect. Dis. 2021;21(1):421. DOI: https://doi.org/10.1186/s12879-021-06103-w</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Yamaguchi M. Investigation of pneumococcal virulence factors in the infection process. Nihon Saikingaku Zasshi. 2020;75(2): 173–83. DOI: https://doi.org/10.3412/jsb.75.173 (in Japanese)</mixed-citation></ref></ref-list></back></article>
